Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The stock's fall snapped a two-day winning streak.

there is still an expectation of some pretty high premiums in the market," he said. The CEO said Biogen has "teams of people" at the healthcare conference this week. At last year's meeting ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get the Real Story Behind Every Major Earnings Report ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from longtime partner Biogen Inc. on the eve of the biggest biotech event of the year.

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.